Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ameile
2. Aumolertinib Mesylate
3. Almonertinib (mesylate)
4. Hs-10296 Mesylate
5. Rz6i9wx68u
6. Hs-10296 Methanesulfonate
7. Aumolertinib Mesylate [usan]
8. 2134096-06-1
9. 2-propenamide, N-(5-((4-(1-cyclopropyl-1h-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-, Compd. With Methanesulfonate (1:1)
10. N-(5-((4-(1-cyclopropyl-1h-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide Methanesulfonate
11. Eq143 Mesylate
12. Eq-143 Mesylate
13. Unii-rz6i9wx68u
14. Almonertinib Mesilate [who-dd]
15. Ex-a6602
16. Hy-112823a
17. Cs-0066156
| Molecular Weight | 621.8 g/mol |
|---|---|
| Molecular Formula | C31H39N7O5S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 11 |
| Exact Mass | 621.27333854 g/mol |
| Monoisotopic Mass | 621.27333854 g/mol |
| Topological Polar Surface Area | 150 Ų |
| Heavy Atom Count | 44 |
| Formal Charge | 0 |
| Complexity | 916 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
ABOUT THIS PAGE
A Aumolertinib Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aumolertinib Mesylate, including repackagers and relabelers. The FDA regulates Aumolertinib Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aumolertinib Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Aumolertinib Mesylate supplier is an individual or a company that provides Aumolertinib Mesylate active pharmaceutical ingredient (API) or Aumolertinib Mesylate finished formulations upon request. The Aumolertinib Mesylate suppliers may include Aumolertinib Mesylate API manufacturers, exporters, distributors and traders.
Aumolertinib Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aumolertinib Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aumolertinib Mesylate GMP manufacturer or Aumolertinib Mesylate GMP API supplier for your needs.
A Aumolertinib Mesylate CoA (Certificate of Analysis) is a formal document that attests to Aumolertinib Mesylate's compliance with Aumolertinib Mesylate specifications and serves as a tool for batch-level quality control.
Aumolertinib Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Aumolertinib Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aumolertinib Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Aumolertinib Mesylate EP), Aumolertinib Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aumolertinib Mesylate USP).
LOOKING FOR A SUPPLIER?
